Phase II trial of methotrexate in myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1275, Issue 1, 2012, Pages 23-28

  Pasnoor, Mamatha ^a   He, Jianghua ^a   Herbelin, Laura ^a   Dimachkie, Mazen ^a   Barohn, Richard J ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Area under the curve; Methotrexate; Myasthenia gravis; Prednisone

Indexed keywords

METHOTREXATE; PREDNISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MYASTHENIA GRAVIS; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 84871601659     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06804.x     Document Type: Article

References (42)

1. Sanders, D., M. McDermott, C. Thornton, et al. 2007. A trial of mycophenolate mofetil (MMF) with prednisone as initial immunotherapy in myasthenia gravis (MG) [abstract]. Neurology 62(Suppl 1): 107.
2. Sanders, D.B., I.K. Hart, R. Mantegazza, et al. 2008. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71(6): 400-406.
3. Sanders, D. & Z. Siddiqi. 2008. Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann. N.Y. Acad. Sci. 1132: 249-253.
4. The Muscle Study Group. 2008. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71: 394-399.
5. Furst, D.F. & J.M. Kremer. 1988. Methotrexate in rheumatoid arthritis. Arthritis Rheum. 31: 305-314.
6. Hirata, S., T. Matsubara, R. Saura, et al. 1989. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 3: 1065-1073.
7. Kremer, J.M. & J.K. Lee. 1988. A long term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months. Arthritis Rheum. 31: 577-584.
8. Lange, F., E. Bajtner, C. Rintisch, et al. 2005. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann. Rheum. Dis. 64: 599-605.
9. Nakajima, A., M. Hakoda, H. Yamanaka, et al. 1996. Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis. Ann. Rheum. Dis. 55: 237-42.
10. Rau, R., G. Herborn, T. Karger & D. Werdier. 1991. Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy. Arthritis Rheum. 34: 1236-1244.
11. Segal, R., E. Mozes, M. Yaron & B. Tartakovsky. 1989. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 32: 370-7.
12. Weinblatt, M.E., B.N. Weissman, D.E. Holdsworth, et al. 1992. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum. 35: 129-137.
13. Currier, R.D., A.F. Haerer & E.F. Meydrech. 1993. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J. Neurol. Neurosurg. Psych. 56: 1217-18.
14. Goodkin, D.E., R.A. Rudick, S. VanderBrug Medendorp, et al. 1995. Low dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 37: 30-40.
15. Goodkin, D.E., R.A. Rudick, S. VanderBrug Medendorp, et al. 1996. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 47: 1153-1157.
16. Abdou, A.M. 2007. Methotrexate for treatment of myasthenia gravis. Neurology 62(Suppl 1): 300-301.
17. Hartmann, J. & M.H. Rivner. 2009. Methotrexate in myasthenia gravis. Clin. Neurophysiol. 120: e123-e124.
18. Heckmann, J.M., A. Rawoot, K. Bateman, et al. 2011. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 11: 97.
19. Raja, F.M., M.M. Dimachkie, A.L. McVey, et al. 2009. Methotrexate in the treatment of myasthenia gravis. Neurology 72(Suppl 3): A54.
20. Calabresi, P. & B. Chabner. 1990. Antineoplastic agents. In The Pharmalogical Basis of Therapeutics. 8th ed. A. Gilman, T. Rall, A. Nies & P. Taylor, Eds.: 1209-1263. Pergamon. New York.
21. Chabner, B.A., C.J. Allegra, G.A. Curt, et al. 1985. Polyglutamation of Methotrexate. Is Methotrexate a pro drug J. Clin. Invest. 76: 907-912.
22. Ifergan, I., A. Shafran, G. Jansen, et al. 2004. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J. Biol. Chem. 279: 25527.
23. Volker, L. & E. Schneider. 2003. Wild type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 63: 5538-5543.
24. Lafforgue, P., S. Monjanel-Mouterde, A. Durand, et al. 1995. Lack of correlation between pharamkokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J. Rheum. 22: 844-849.
25. Ravelli, A., G. Di Fuccia, M. Molinaro, et al. 1993. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J. Rheum. 20: 1573-1577.
26. Wallace, C.A., W.A. Bleyer, D.D. Sherry, et al. 1989. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum. 32: 677-681.
27. Dervieux, T., J. Kremer, D. Orentas Lein, et al. 2004. Contribution of common polymorphisms in reduced folate carrier and γ-glutamylhydrolase to Methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14: 733-739.
28. Derivieux, T., D. Furst, D. Orentas Lein, et al. 2005. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with Methotrexate: results of a multicentered cross sectional observational study. Ann. Rheum. Dis. 64: 1180-1185.
29. Herbert, V. 1987. Making sense of laboratory tests of folate status: folate requirements to sustain normality. Am. J. Hematol. 26: 199-207.
30. Dalrymple, J.M., L.K. Stamp, J.L. O'Donnell, et al. 2008. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 58: 3299-3308.
31. Stamp, L.K., J.L. O'Donnell, P.T. Chapman, et al. 2009. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum. 60: 2248-2256.
32. Benatar, M., D.B. Sanders, T.M. Burns, et al. 2012. Recommendations for myasthenia gravis clinical trials. Muscle Nerve 45: 909-917.
33. Mertens, H.G., P. Hertel, P. Reuther & K. Ricker. 1981. Effect of immunosuppressive drugs (azathioprine). Ann. N.Y. Acad. Sci. 377: 691-699.
34. Palace, J., J. Newsom-Davis & B. Lecky. 1998. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50: 1778-1783.
35. Drachman, D.B., R.J. Jones & R.A. Brodsky. 2003. Treatment of refractory myasthenia: "Rebooting" with high-dose cyclophosphamide. Ann. Neurol. 53: 29-34.
36. Tindall R.S.A., J.A. Rollins, J.T. Phillips, et al. 1987. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N. Engl. J. Med. 316: 719-724.
37. Tindall, R.S.A., J.T. Phillips, J.A. Rollins, et al. 1992. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. N.Y. Acad. Sci. 681: 539-551.
38. Zinman, L., E. Ng & V. Bril. 2007. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68: 837-841.
39. Wolfe, G.I., R.J. Barohn, B.M. Foster, et al. 2002. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 26: 549-552.
40. Kissel, J.T., R.j. Levy, J.R. Mendell & R.C. Griggs. 1986. Azathioprine toxicity in neuromuscular disease. Neurology 36: 35-39.
41. Dau, P.C., J.M. Lindstrom, C.K. Cassel, et al. 1977. Plasmaphereses and immunosuppressive drug therapy in myasthenia gravis. N. Engl. J. Med. 297: 1134-1140.
42. Jaretzski, A., III, R.J. Barohn, R.M. Ernstoff, et al. 2000. Myasthenia gravis: recommendations for clinical research standards. Ann. Thorac. Surg. 70: 327-334.